China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug RFUS-144, designed to relieve pain and itching. This marks a significant step forward in the company’s efforts to develop innovative therapies for pain management.
Drug Profile and Market Potential
RFUS-144 is a selective opioid agonist with no similar product commercially available in China. The global pain management market reached USD 3.47 billion in 2021, with opioid analgesics accounting for 66.8% of the market share. This approval positions Humanwell to potentially capture a significant portion of this growing market with its novel therapeutic option.-Fineline Info & Tech
